Hu Cheng, Jia Weiping
Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Institute for Metabolic Disease, Fengxian Central Hospital, The Third School of Clinical Medicine, Southern Medical University, Shanghai 201499, China.
J Mol Cell Biol. 2021 Aug 18;13(8):576-93. doi: 10.1093/jmcb/mjab051.
Metabolic diseases including type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome (MetS) are alarming health burdens around the world, while therapies for these diseases are far from satisfying as their etiologies are not completely clear yet. T2DM, NAFLD, and MetS are all complex and multifactorial metabolic disorders based on the interactions between genetics and environment. Omics studies such as genetics, transcriptomics, epigenetics, proteomics, and metabolomics are all promising approaches in accurately characterizing these diseases. And the most effective treatments for individuals can be achieved via omics pathways, which is the theme of precision medicine. In this review, we summarized the multi-omics studies of T2DM, NAFLD, and MetS in recent years, provided a theoretical basis for their pathogenesis and the effective prevention and treatment, and highlighted the biomarkers and future strategies for precision medicine.
包括2型糖尿病(T2DM)、非酒精性脂肪性肝病(NAFLD)和代谢综合征(MetS)在内的代谢性疾病是全球令人担忧的健康负担,而针对这些疾病的治疗方法远不能令人满意,因为它们的病因尚未完全明确。T2DM、NAFLD和MetS都是基于遗传与环境相互作用的复杂多因素代谢紊乱疾病。遗传学、转录组学、表观遗传学、蛋白质组学和代谢组学等组学研究都是准确表征这些疾病的有前景的方法。通过组学途径可以为个体实现最有效的治疗,这也是精准医学的主题。在本综述中,我们总结了近年来T2DM、NAFLD和MetS的多组学研究,为它们的发病机制以及有效预防和治疗提供了理论基础,并强调了精准医学的生物标志物和未来策略。